Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics

Epilepsy Research

Volumn 115, Issue , 2015, Pages 55-57

  Keezer, Mark R ^a,b   Novy, Jan ^a,c   Sander, Josemir W ^a,b,d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Anti glutamic acid decarboxylase antibodies; Comorbidity; Epidemiology; Pharmacoresistant; Prevalence

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DRUG RESISTANT EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEMPORAL LOBE EPILEPSY; TERTIARY CARE CENTER; UNITED KINGDOM; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR;

ADULT; DIABETES MELLITUS, TYPE 1; DRUG RESISTANT EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 84937831056     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.05.008     Document Type: Article

References (14)

1. Berg A.T., Berkovic S.F., Brodie M.J., et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
2. Caietta E., Halbert C., Lepine A., et al. [Association of type 1 diabetes mellitus and epilepsy in children. A cohort of 10 cases]. Arch. Pediatr. 2012, 19:9-16.
3. Ellis T.M., Atkinson M.A. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat. Med. 1996, 2:148-153.
4. Feltbower R.G., McKinney P.A., Campbell F.M., et al. Type 2 and other forms of diabetes in 0-30 year olds: a hospital based study in Leeds, UK. Arch. Dis. Child. 2003, 88:676-679.
5. Gaitatzis A., Sisodiya S.M., Sander J.W. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012, 53:1282-1293.
6. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006, 118:1510-1518. Group SfDiYS.
7. Kwan P., Sills G.J., Kelly K., et al. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res. 2000, 42:191-195.
8. Liimatainen S., Peltola M., Sabater L., et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010, 51:760-767.
9. McCorry D., Nicolson A., Smith D., et al. An association between type 1 diabetes and idiopathic generalized epilepsy. Ann. Neurol. 2006, 59:204-206.
10. Nemni R., Braghi S., Natali-Sora M.G., et al. Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann. Neurol. 1994, 36:665-667.
11. O'Connell M.A., Harvey A.S., Mackay M.T., et al. Does epilepsy occur more frequently in children with Type 1 diabetes?. J. Paediatr. Child Health. 2008, 44:586-589.
12. Peltola J., Kulmala P., Isojarvi J., et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000, 55:46-50.
13. Thurman D.J., Beghi E., Begley C.E., et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011, 52(Suppl 7):2-26.
14. Vincent A., Bien C.G., Irani S.R., et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011, 10:759-772.